Comparison |
| Application |
| Human Papillomavirus Vaccine (HPV) | Td Vaccine | Pneumonia Vaccine | MMR Vaccine |
| Container Type |
| Prefilled Syringe | Single-Dose Vial | Prefilled Syringe | Single-Dose Vial |
| Country of Origin |
Unknown | United States | Unknown | United States | United States |
| Dosage Form |
| Injection | Injection | Injection | Injection |
| Generic Drug Code |
| 37568 | 20835 | 43859 | 99568 |
| Generic Drug Name |
| Human Papillomavirus 9-Valent Vaccine, Recombinant, Preservative Free | Tetanus and Diphtheria Toxoids Adsorbed | Pneumococcal 23 Vaccine Polyvalent | Measles, Mumps, and Rubella Vaccine, Preservative Free |
| NDC Number |
| 00006412102 | 13533013101 | 00006483703 | 00006468100 |
| Product Dating |
| McKesson Acceptable Dating: we will ship >= 180 days | McKesson Acceptable Dating: we will ship >= 180 days | McKesson Acceptable Dating: we will ship >= 180 days | McKesson Acceptable Dating: we will ship >= 90 days |
| Storage Requirements |
| Requires Refrigeration | Requires Refrigeration | Requires Refrigeration | Requires Refrigeration |
| Strength |
| 20 mcg - 60 mcg / 0.5 mL | 2 Lf - 2 Lf / 0.5 mL | 25 mcg / 0.5 mL | 1,000 TCID - 12,500 TCID - 1,000 TCID / 0.5 mL |
| Type |
| Intramuscular | Intramuscular | Intramuscular or Subcutaneous | Intravenous or Subcutaneous |
| UNSPSC Code |
| 51201649 | 51201629 | 51201615 | 51201628 |
| User |
| Indicated for People 9 to 45 Years of Age | Indicated for People 7 Years of Age and Older | Indicated for People 50 Years of Age and Older | Indicated for People 12 Months of Age and Older |
| Volume |
| 0.5 mL | 0.5 mL | 0.5 mL | 0.5 mL |
| Features and Benefits |
|
- GARDASIL 9 is a non-infectious recombinant 9-valent vaccine prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58
- Each 0.5-mL dose contains approximately 30 mcg of HPV Type 6 L1 protein, 40 mcg of HPV Type 11 L1 protein, 60 mcg of HPV Type 16 L1 protein, 40 mcg of HPV Type 18 L1 protein, 20 mcg of HPV Type 31 L1 protein, 20 mcg of HPV Type 33 L1 protein, 20 mcg of HPV Type 45 L1 protein, 20 mcg of HPV Type 52 L1 protein, and 20 mcg of HPV Type 58 L1 protein
- Administer GARDASIL 9 intramuscularly as a 0.5-mL dose at the following schedule: 0, 2 months, 6 months
- Not all vulvar, vaginal, and anal cancers are caused by HPV, and GARDASIL 9 protects only against those vulvar, vaginal, and anal cancers caused by HPV 16, 18, 31, 33, 45, 52 and 58
|
|
- PNEUMOVAX 23 is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine
- PNEUMOVAX 23 is approved for use in persons 50 years of age or older and persons aged >2 years who are at increased risk for pneumococcal disease
- Box of 10 single-dose, pre-filled Luer-Lok™ syringes with tip caps, color coded with a violet plunger rod and purple stripe on the syringe labels and cartons
- Store unopened and opened vials at 2° - 8°C (36° - 46°F)
|
- Preservative free
- M-M-R II* is supplied as: (1) a box of 10 single-dose vials of lyophilized vaccine and (2) a box of 10 vials of diluent
- Store vials at 2 - 8 degrees Celsius (36 - 46 degrees Fahrenheit)
- The diluent may be stored in the refrigerator with the lyophilized vaccine or separately at room temperature
|
